Olanib (Olaparib INN) 150 mg

£0.00

Olanib, which incorporates Olaparib as its International Nonproprietary Name (INN), is predominantly used in treating specific cancer types, notably ovarian, breast, and pancreatic cancer. Functioning as a poly (ADP-ribose) polymerase (PARP) inhibitor, Olanib interferes with DNA repair processes in cancer cells, prompting their demise. The typical Olanib dosage entails 150 mg taken orally twice daily, with or without food. Patients may encounter side effects like nausea, fatigue, anemia, and abdominal discomfort during Olanib treatment. Regular monitoring and discussions with healthcare providers are crucial during Olanib therapy to address potential side effects and ensure favorable treatment outcomes.

Add to wishlist
Share

    Indications: Olaparib (INN) 150 mg is prescribed for various cancers:

    • Ovarian cancer: as maintenance therapy post platinum-based chemotherapy.
    • Breast cancer: for metastatic HER2-negative breast cancer in patients with BRCA mutations.
    • Pancreatic cancer: for metastatic cases in patients with BRCA mutations after chemotherapy.

    Pharmacology: Olaparib blocks PARP enzymes, disrupting DNA repair, particularly in cells with BRCA mutations, inducing cancer cell death.

    Dosage and Administration: The standard dose of Olaparib is 300 mg twice daily, but for Olaparib 150 mg tablets, it’s usually one tablet twice daily. Dosage adjustments might be needed based on individual response and side effects, taken with or without food.

    Interactions: Olaparib can interact with other medications, so patients should inform their healthcare providers about all medications, including supplements.

    Side Effects: Common side effects include nausea, vomiting, fatigue, anemia, reduced appetite, diarrhea, and abdominal pain. Serious effects may include bone marrow suppression and increased cancer risks.

    Precautions and Warnings: Olaparib may induce bone marrow suppression and increased cancer risks, requiring regular blood tests and vigilant monitoring.

    Overdose Effects: Overdose management involves supportive measures, as there’s no specific antidote. Treatment focuses on alleviating symptoms.

    Product Name

    Olanib

    Generic Name

    Olaparib INN

    Formulation

    Tablet

    Available Pack size

    120 Tablets

    Strengths

    150 mg

    Reviews

    There are no reviews yet.

    Be the first to review “Olanib (Olaparib INN) 150 mg”